Founded Year
2015Stage
Series B | AliveTotal Raised
$19.7MLast Raised
$19.7M | 4 yrs agoMissing: Pi Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Pi Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Pi Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Pi Therapeutics is included in 2 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Pi Therapeutics Patents
Pi Therapeutics has filed 1 patent.
The 3 most popular patent topics include:
- Cell biology
- Experimental cancer drugs
- Monoclonal antibodies

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
3/7/2019 | Experimental cancer drugs, Monoclonal antibodies, Monoclonal antibodies for tumors, Proteins, Cell biology | Application |
Application Date | 3/7/2019 |
---|---|
Grant Date | |
Title | |
Related Topics | Experimental cancer drugs, Monoclonal antibodies, Monoclonal antibodies for tumors, Proteins, Cell biology |
Status | Application |
Latest Pi Therapeutics News
Mar 10, 2020
MedCity News Israel’s Arkin Holdings raises $140M for second life sciences investment fund The company, based near Tel Aviv, said it plans to invest money from the fund, Arkin Bio-Ventures II, in areas like gene therapy, as well as RNA- and DNA-targeted drugs. Shares0 An Israeli life sciences investment firm is raising more than $100 million for a new fund that it plans to invest in about a dozen companies that are developing medicines in areas like gene therapy. Arkin Holdings, based in Herzliya Pituach, near Tel Aviv, said Monday that it was raising $140 million for the fund, named Arkin Bio-Ventures II. Arkin itself, as well as fellow Israeli institutional investors Migdal and the Phoenix Group, have committed to providing money to the fund, which will invest in areas like gene therapy, RNA- and DNA-based therapies and targeted therapies. “Arkin Bio-Ventures II builds on the success of our earlier, well-established and lucrative fund,” Arkin Holdings Chairman Mori Arkin said in a statement. “Together with our partners, we look forward to further successful investments in novel and world-class technologies and organizations.” The company launched a $60 million fund for life sciences investment in June 2016, together with The Phoenix Group, which took a 49% stake in the partnership. Other moves have included a partnership with Shanghai-based WuXi AppTec and Daarmstadt, Germany-based Merck KGaA – not to be confused with U.S.-based Merck & Co. – for the February 2018 launch of ExploreBio, an Israel-based biotech incubator. Arkin’s website highlights 10 companies that it has funded, including those in which it remains invested and those that have exited, such as UroGen Pharma, MetaboMed, Pi Therapeutics, Redpin Therapeutics, BioSight, Lutris Pharma and CCAM Biotherapeutics. Last May, Pi Therapeutics raised $19.7 million in a venture capital funding round, according to Israeli news media. Some of Arkin’s portfolio companies are in relatively advanced stages of clinical development as well. In June 2018, BioSight launched a Phase IIb study of one of its drugs, BST-236, in first-line acute myeloid leukemia. The company announced in February that it would bring in Migdal as an anchor investor, thereby increasing its investment scope in the biomedical industry to $1.4 billion. Photo: Feodora Chiosea, Getty Images Promoted
Pi Therapeutics Frequently Asked Questions (FAQ)
When was Pi Therapeutics founded?
Pi Therapeutics was founded in 2015.
Where is Pi Therapeutics's headquarters?
Pi Therapeutics's headquarters is located at Ness Ziona.
What is Pi Therapeutics's latest funding round?
Pi Therapeutics's latest funding round is Series B.
How much did Pi Therapeutics raise?
Pi Therapeutics raised a total of $19.7M.
Who are the investors of Pi Therapeutics?
Investors of Pi Therapeutics include Pontifax, RM Global Partners, Arkin Holdings, Quark Venture, GF Securities and 3 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.